Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MT-ATP6 is a 226-amino acid, mitochondrially encoded integral membrane protein forming part of the F₀ sector of the ATP synthase complex (complex V) in the mitochondrial inner membrane[1][2]. It is responsible for facilitating proton translocation together with subunit c, forming the core of the mitochondrial proton channel required for ATP production[3][5]. The proton gradient generated by upstream electron transport complexes is utilized by ATP synthase via the rotary mechanism of the F₁ and F₀ domains, converting ADP and phosphate to ATP—the universal energy currency of the cell[1][2][3]. Pathogenic mutations in MT-ATP6 impair ATP generation and are strongly linked to Leigh syndrome and other mitochondrial encephalopathies[4]. Pharmacologic inhibition of ATP synthase F₀ (e.g., by oligomycin) blocks ATP synthesis and can be lethal due to failure of energy conversion in all tissues[1][5][4].
Inhibition of proton flow (oligomycin, DCCD block the F₀ channel) Impairment of ATP synthesis (energy production blockade) Uncoupling of proton gradient and ATP production
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP synthase F₀ complex subunit a, mitochondrially encoded (MT-ATP6).